

Choice of outcome measures for the VISION pilot trial of interventions for hemianopia

Dear Editor,

We thank Bowers et al.¹ for their considered comments of the VISION pilot trial results.

The primary queries raised by Bowers et al. relate to the selection of the primary and secondary outcome measures in the VISION trial. The primary outcome was change in visual field area from baseline to 26 weeks, and the secondary measures were the Rivermead Mobility Index, Visual Function Questionnaire 25/10, Nottingham Extended Activities of Daily Living, EuroQol, Short Form-12 questionnaire and Radner reading ability. The VISION trial was planned in 2009 and, based on the available evidence at that time, the choice of outcome measures was appropriate, as we explain below.

VISION trial planning preceded the publication of a Cochrane systematic review on interventions for visual field loss following stroke.² Thus, a literature review by the trial team in 2009 reviewed the outcome measures reported by others [eg, ³⁻¹³]. From this review, for all studies reporting outcomes for visual scanning training, visual field assessment was the only outcome measure (as a primary or secondary outcome measure) consistently used across all studies. For studies reporting outcomes for prism wear, all but one study¹⁰ reported visual field assessment (with/without prism to consider field expansion effect).

As visual field assessment was consistently measured in all the key previous studies, it was an important outcome measure to consider in the VISION trial. Previous studies of interventions for hemianopia, particularly visual scanning training, had reported some apparent recovery in visual field defects (measured by visual field assessment) despite no change in objective measurements of visual field defect boundary. This was reported as being due to compensatory processes including better stimuli detection and faster reaction times to stimuli in the hemianopic field, along with unstable central fixation with eye movements towards the hemianopic side.¹⁴⁻¹⁷ However, there was insufficient information on the extent of variations that might occur in visual field measurements with natural adaptation (captured through the control arm) versus adaptation following different interventions (visual scanning training or prism therapy); we wished to explore this further.

Participants in the VISION trial could be recruited from 2 weeks to 6 months post-stroke onset. Bowers et al. correctly note that "prior research suggests there may be spontaneous recovery of the visual field up to 3-6 months following stroke".^{18,19} Because of this, many

studies recruit participants after at least 6 months post-stroke onset to ensure stability of hemianopia. However, it is also known that about half of stroke survivors with hemianopia show no recovery of visual field loss^{18,19} and notably there are a number of reported studies that recruited participants with hemianopia at earlier time periods.^{3,5,6,9} A further advantage of measuring relative change in visual field over time was that it allowed us to explore the acknowledged risk of possible natural recovery over several time points of baseline through to 6, 12 and 26 weeks.^{2,14,20}

Bowers et al. query the value of computing sample sizes for various minimally clinically important changes in visual field data as a basis for sample size calculations for future trials. We would agree these calculations are no longer of practical relevance. However, as generating these calculations was one of the objectives of the trial, it was important to include them for completeness and to avoid reporting bias. As Bowers et al. have correctly identified, we stated in our conclusions that alternative primary outcome measurement should be considered for future clinical trials. We recognize that, considering the current 2017 evidence base, other outcome measures, specifically vision- and health-related quality-of-life instruments, are now more important.

In our pretrial literature review, additional reported outcome measures included blind side detection rates, eye movement recordings, quality-of-life questionnaires, reading rates and patient perceptions of treatment, continued prism wear and participant ratings of prism helpfulness, and falls amongst others. However, none of these were used consistently across all studies. The majority of the VISION secondary outcome measures related to activities of daily living performance and quality-of-life instruments. A Cochrane systematic review for interventions for hemianopia² concluded that further trials should specifically concentrate on functional and quality-of-life outcomes. Although this was published after VISION had started, we had already recognized this lack of functional outcome measures in previous studies. An objective of the pilot trial was therefore to explore quality of life and activities of daily life; appropriate measures were selected.

In the absence of consistent choice of functional activity outcome measures evident from our literature review, decisions about outcomes were made by expert stroke clinicians (physicians, occupational therapists and physiotherapists with clinical trial methodological expertise). The choice of vision-related quality-of-life measure was the NIH VFQ-25 questionnaire. This questionnaire was used in previous quality-of-life studies²¹⁻²³ showing significant reduction in quality of

life for participants with hemianopia. In the absence of any vision-related quality-of-life measure specifically developed for stroke/vision research or clinical practice, the choice of VFQ-25 was appropriate, given its prior²¹⁻²³ and, of note, continued^{24,25} use in research with stroke survivors with hemianopia. Indeed, a recent systematic review of the evidence base for appropriate quality-of-life measures for stroke-related visual impairment highlighted the VFQ-25 as one of very few instruments with potential in such trials.²⁶ Hepworth and colleagues²⁶ found no instruments that were developed specifically for visual impairment following stroke or which involved stroke survivors in the item identification phase of instrument development; they recommended further research to address this. Until such a stroke/vision-specific questionnaire is developed, we believe that the VFQ-25 remains an appropriate choice of vision-related quality-of-life measure. A further advantage of choosing the VFQ-25 questionnaire was, because of its widespread use, comparisons can be made to other populations of visual impairment in the future. Bowers et al. note the limited justification and discussion of all outcome measures. It was difficult within the word limit to provide justification and detailed explanations for every outcome measure. In recognition of this, a separate results paper for our VFQ-25 data is being considered.

An important outcome measure to include in any intervention trial is adverse event rate. The VISION trial sought to ensure that these were reported specific to the time period when interventions were used (ie, whilst wearing prism glasses or completing visual search training) highlighting a considerable difference between groups of 69% reported adverse events for the prism group and 7% for the visual search training group (0% for standard care). When planning the use of participant diaries, a key consideration was to ensure that participants could report their perceptions of intervention freely without clinician influence. We took specific care to ensure that participant diaries were completed at home and were reviewed only by independent blinded assessors.

A final aspect we should like to highlight is adherence to the CONSORT guidance when reporting trials. We followed the correct procedures of publishing our trial protocol²⁷ and ensured that the trial was conducted according to the predetermined design. When publishing the final results of the trial, we adhered to CONSORT reporting guidelines and reported all the outcome measures stipulated in the protocol.

In conclusion, it is positive to see the emerging research for treatment of hemianopia since 2009. Clearly any new research planned for treatment of hemianopia should consider the current evidence base. The choice of outcome measures must be chosen wisely, and we have highlighted in the VISION trial conclusions that alternative outcome measures should be considered if planning future clinical trials of multiple interventions for hemianopia. The evidence base will change and, consequently, when eventually reporting and interpreting results, this must be taken into consideration.

ACKNOWLEDGEMENT

FR had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

We would like to thank the patients and staff who participated in this trial and the following collaborators and investigators: Isabel Ash, Conrad Beacham, Rachel Breen, Judith Burn, Carol Buckley, Joanne Gardiner, Henrietta Holmes-Smith, Sandra Knowles, Tallat Maan, Sonia MacDiarmid, Lorraine North, Leonie Ripley, Claire Scott, Sarah Spencer, Andrew Twigg, Carole-Anne Vince, Data Monitoring Committee (Cicely Freeman, Irene Stratton, David Wright), Trial Steering Committee (Darren Brand, Catie Bunce, Anne-Marie Mackay, Sarah Peel).

FUNDING INFORMATION

This trial was funded by the Stroke Association, UK.

CONFLICT OF INTERESTS

No conflicting relationship exists for any author.

COMPETING INTERESTS

This trial is funded by the UK Stroke Association which includes salaries for EC. The sponsor (University of Liverpool Research Support Office) and funder (the Stroke Organisation) had no role in the study design, collection, management, analysis, interpretation of data, writing of the report and the decision to submit the protocol for publication.

F. J. Rowe¹ 

E. J. Conroy²

E. Bedson³

E. Cwiklinski³

A. Drummond⁴

M. García- Fiñana²

C. Howard⁵

A. Pollock⁶

T. Shipman⁷

C. Dodridge⁸

C. MacIntosh⁸

S. Johnson⁹

C. Noonan¹⁰

G. Barton¹¹

C. Sackley¹²

¹Department of Health Services Research, University of Liverpool, Liverpool, UK

²Department of Biostatistics, University of Liverpool, Liverpool, UK

³Clinical Trials Research Unit, University of Liverpool, Liverpool, UK

⁴School of Health Sciences, University of Nottingham, Nottingham, UK

⁵Department of Orthoptics, Salford Royal NHS Foundation Trust, Manchester, UK

⁶Nursing Midwifery and Allied Health Professions Research Unit, Glasgow Caledonian University, Glasgow, UK

⁷Department of Orthoptics, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK

⁸Department of Orthoptics, Oxford University Hospitals NHS Trust, Oxford, UK

⁹Eye Clinic Impact Team, Royal National Institute for the Blind, Birmingham, UK

¹⁰Department of Ophthalmology, Aintree University Hospital NHS Foundation Trust, Liverpool, UK

¹¹Department of Elderly Care, Warrington and Halton Hospitals NHS Foundation Trust, Warrington, UK

¹²Division of Health and Social Care, King's College, London, UK
Email: rowef@liverpool.ac.uk

REFERENCES

- Rowe FJ, Conroy EJ, Bedson E, et al. A pilot randomized controlled trial comparing effectiveness of prism glasses, visual search training and standard care in hemianopia. *Acta Neurol Scand*. 2016;00:1-12. <https://doi.org/10.1111/ane.12725>
- Pollock A, Hazelton C, Henderson CA, et al. Interventions for visual field defects in patients with stroke. *Cochrane Database Syst Rev*. 2011;(10). Art. No: CD008388 <https://doi.org/10.1002/14651858.cd008388.pub2>
- Weinberg J, Diller L, Gordon WA, et al. Training sensory awareness and spatial organization in people with right brain damage. *Arch Phys Med Rehabil*. 1979;60:491-496.
- Kerkhoff G, Munßinger U, Haaf E, Eberle-Strauss G, Stogerer E. Rehabilitation of homonymous scotomata in patients with postgeniculate damage of the visual system: saccadic compensation training. *Restor Neurol Neurosci*. 1992b;4:245-254.
- Carter LT, Howard BE, O'Neil WA. Effectiveness of cognitive skill remediation in acute stroke patients. *Am J Occup Ther*. 1983;37:320-326.
- Rossi PW, Kheyfets S, Reding MJ. Fresnel prisms improve visual perception in stroke patients with homonymous hemianopia or unilateral visual neglect. *Neurology*. 1990;40:1597-1599.
- Pambakian AL, Mannan SK, Hodgson TL, Kennard C. Saccadic visual search training: a treatment for patients with homonymous hemianopia. *J Neurol Neurosurg Psychiatr*. 2004;75:1443-1448.
- Riggs RV, Andrews K, Roberts P, Gilewski M. Visual deficit interventions in adult stroke and brain injury. *Am J Phys Med Rehabil*. 2007;86:853-860.
- Zihl J. Visual scanning behaviour in patients with homonymous hemianopia. *Neuropsychologia*. 1995;33:287-303.
- Bowers AR, Keeney K, Peli E. Community-based trial of a peripheral prism visual field expansion device for hemianopia. *Arch Ophthalmol*. 2008;126:657-664.
- Giorgi RG, Woods RI, Peli E. Clinical and laboratory evaluation of peripheral prism glasses for hemianopia. *Optom Vis Sci*. 2009;86:492-502.
- Peli E. Field expansion for homonymous hemianopia by optically induced peripheral exotropia. *Optom Vis Sci*. 2000;77:453-464.
- Bainbridge W, Reding M. Full-field prisms for hemi-field visual impairments following stroke: a controlled trial. *Neurology*. 1994;44(Suppl 2):A312-A313.
- Nelles G, Pscherer A, de Greiff A, et al. Eye movement training-induced changes of visual field representation in patients with post-stroke hemianopia. *J Neurol*. 2010;257:1832-1840.
- Nelles G, Esser J, Eckstein A, Tiede A, Gerhard H, Diener H. Compensatory visual field training in recovery from hemianopia after stroke. *Neurosci Lett*. 2001;306:192-198.
- Roth T, Sokolov AN, Messias A, Roth P, Waller M, Trauzettel-Klosinski S. Comparing explorative saccade and flicker training in hemianopia. *Neurology*. 2009;72:324-331.
- Trauzettel-Klosinski S, Reinhard J. The vertical field border in hemianopia and its significance for fixation and reading. *Invest Ophthalmol Vis Sci*. 1998;39:2177-2186.
- Gray CS, French JM, Bates D, Cartlidge NEF, Venables GS, James ORW. Recovery of visual fields in acute stroke: homonymous hemianopia associated with adverse prognosis. *Age Ageing*. 1989;18:419-421.
- Zhang X, Kedar S, Lynn MJ, Newman NJ, Biousse V. Natural history of homonymous hemianopia. *Neurology*. 2006;66:901-905.
- Lane AR, Smith DT, Ellison A, Schenk T. Visual exploration training is no better than attention training for treating hemianopia. *Brain*. 2010;133:1717-1728.
- Chen CS, Lee AW, Clarke G, et al. Vision-related quality of life in patients with complete homonymous hemianopia post stroke. *Top Stroke Rehabil*. 2009;16:445-453.
- Gall C, Lucklum J, Sabel BA, Franke GH. Vision and health-related quality of life in patients with visual field loss after postchiasmatic lesions. *Invest Ophthalmol Vis Sci*. 2009;50:2765-2776.
- Papageorgiou E, Hardiess G, Schaeffel F, et al. Assessment of vision related quality of life in subjects with homonymous visual field defects. *Graefes Arch Clin Exp Ophthalmol*. 2007;245:1749-1758.
- Gall C, Franke GH, Sabel BA. Vision-related quality of life in first stroke patients with homonymous visual field defects. *Health Qual Life Outcomes*. 2010;8:1-15.
- George S, Hayes A, Chen C, Crotty M. Are vision-specific quality of life questionnaires important in assessing rehabilitation for patients with hemianopia post stroke? *Top Stroke Rehabil*. 2011;18:394-401.
- Hepworth LR, Rowe FJ, Harper R, Jarvis K, Shipman T, Rodgers H. Patient reported outcome measures for visual impairment after stroke: a systematic review. *Health Qual Life Outcomes*. 2015;13:146. <https://doi.org/10.1186/s12955-015-0338-x>
- Rowe FJ, Barton PG, Bedson E, et al. A randomised controlled trial to compare the clinical and cost-effectiveness of prism glasses, visual search training and standard care in patients with hemianopia following stroke: a protocol. *BMJ Open*. 2014;4:e005885.